- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT00482014
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
Phase 1/2 Study of Pemetrexed (Alimta) Plus Carboplatin, or Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients With Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer (NSCLC)
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 2. fázis
- 1. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
California
-
Los Angeles, California, Egyesült Államok, 90095
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Kansas
-
Wichita, Kansas, Egyesült Államok, 67214
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Missouri
-
St Louis, Missouri, Egyesült Államok, 63110
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Nevada
-
Las Vegas, Nevada, Egyesült Államok, 89135
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
North Carolina
-
Burlington, North Carolina, Egyesült Államok, 27216
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Tennessee
-
Memphis, Tennessee, Egyesült Államok, 38120
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Texas
-
Corpus Christi, Texas, Egyesült Államok, 78405
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Dallas, Texas, Egyesült Államok, 75390
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Temple, Texas, Egyesült Államok, 76508
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Delhi, India, 110085
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Trivandrum, India, 695 011
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Inoperable non small cell lung cancer
- No weight loss greater than 10% in 3 months prior to enrolling in trial
- Adequate kidney function
- Adequate liver function
- Adequate lung function
Exclusion Criteria:
- Previous surgery to remove lung tumor
- Previous chemotherapy or radiation therapy or lung cancer
- Inability to take vitamin supplementation
- Heart attack within past 6 months
- Active infection
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: A: Pemetrexed + Carboplatin
Pemetrexed + Carboplatin
|
Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase
Más nevek:
Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter*minute (mg/mL*min), administered intravenously, Days 1, 8, 22, 29 and 43 Phase 2 - dosed at AUC 5 mg/mL*min, administered intravenously, every 21 days for 3 cycles Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51 Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45 |
Kísérleti: B: Pemetrexed + Cisplatin
Pemetrexed + Cisplatin
|
Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase
Más nevek:
Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51 Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45 Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43 Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin
Időkeret: Phase 1 enrollment to the end of study treatment up to Week 11
|
MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed.
DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (<0.5 x 10^9 cells per liter) lasting >7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever >38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).
|
Phase 1 enrollment to the end of study treatment up to Week 11
|
Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin
Időkeret: Phase 1 enrollment to the end of study treatment up to Week 11
|
MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed.
DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (<0.5 x 10^9 cells per liter) lasting >7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever >38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).
|
Phase 1 enrollment to the end of study treatment up to Week 11
|
Phase 2 - Survival Probability at 2 Years
Időkeret: Phase 2 randomization up to 2 years
|
Phase 2 randomization up to 2 years
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs)
Időkeret: Phase 1 enrollment up to Week 11
|
Phase 1 pharmacology toxicity was defined as the number of participants experiencing dose limiting toxicities (DLTs).
DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course: Grade 4 neutropenia (<0.5 x 10^9 cells per liter) >7 days, febrile neutropenia, ≥Grade 3 neutropenia with fever >38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations), and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).
Grade 5 events are the events leading to the death.
|
Phase 1 enrollment up to Week 11
|
Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate)
Időkeret: Phase 1 enrollment to the end of the study treatment up to Week 11
|
Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines.
CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions.
Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.
|
Phase 1 enrollment to the end of the study treatment up to Week 11
|
Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events
Időkeret: Phase 2 randomization to the end of the study treatment up to 30.0 months
|
Phase 2 pharmacology toxicity was defined as the number of participants who experienced serious adverse events or all other nonserious adverse events during the study.
A summary of serious adverse events and other nonserious adverse events is located in the Reported Adverse Events section.
|
Phase 2 randomization to the end of the study treatment up to 30.0 months
|
Phase 2 - Time to Progression
Időkeret: Phase 2 randomization to measured disease progression up to 24 months
|
Time to disease progression was measured from randomization of Study Phase 2 to the first observation of disease progression according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
Disease progression is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.
|
Phase 2 randomization to measured disease progression up to 24 months
|
Phase 2 - Median Survival
Időkeret: Phase 2 randomization to death as the result of any cause up to 30.0 month
|
Phase 2 randomization to death as the result of any cause up to 30.0 month
|
|
Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate)
Időkeret: Phase 2 randomization to the end of the treatment up to 30.0 months
|
Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines.
CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions.
Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.
|
Phase 2 randomization to the end of the treatment up to 30.0 months
|
Együttműködők és nyomozók
Szponzor
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Becslés)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
- Légúti betegségek
- Neoplazmák
- Tüdőbetegségek
- Neoplazmák webhelyenként
- Légúti neoplazmák
- Mellkasi neoplazmák
- Karcinóma, bronchogén
- Bronchiális neoplazmák
- Tüdő neoplazmák
- Karcinóma, nem kissejtes tüdő
- A farmakológiai hatás molekuláris mechanizmusai
- Nukleinsav szintézis gátlók
- Enzim gátlók
- Antineoplasztikus szerek
- Folsav antagonisták
- Carboplatin
- Pemetrexed
Egyéb vizsgálati azonosító számok
- 9031 (CTEP)
- H3E-US-S047 (Egyéb azonosító: Eli Lilly and Company)
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Nem kissejtes tüdőrák
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.Aktív, nem toborzóÁttétes tüdő nem kissejtes karcinóma | Tűzálló tüdő nem kissejtes karcinóma | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | IVA stádiumú tüdőrák AJCC v8 | IVB stádiumú tüdőrák AJCC v8Egyesült Államok
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor...Aktív, nem toborzóNon-Hodgkin limfóma | B-Cell ALL | B-sejt CLLEgyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)BefejezveAnn Arbor Stage III 1. fokozatú follikuláris limfóma | Ann Arbor Stage III 2. fokozatú follikuláris limfóma | Ann Arbor III. stádiumú indolens felnőtt nem-Hodgkin limfóma | Ann Arbor IV. stádiumú, 1. fokozatú follikuláris limfóma | Ann Arbor IV. stádiumú, 2. fokozatú follikuláris limfóma | Ann... és egyéb feltételekEgyesült Államok
-
Xiangyang No.1 People's HospitalQingdao Haier Biotechnology Co.,Ltd.Még nincs toborzásRefrakter B-sejtes limfóma | B-sejtes limfóma visszatérő | NK CellKína
-
National Cancer Institute (NCI)BefejezveLimfóma | Bőr | T-CellEgyesült Államok
-
National Cancer Institute (NCI)BefejezveElsődleges mediastinalis B-sejtes limfóma | Diffúz, nagy B-sejtes limfóma | Diffúz nagy B-sejtes limfóma follikuláris limfómából átalakulva | Mantle CellEgyesült Államok
-
Merck Sharp & Dohme LLCBefejezveLimfóma, non-Hodgkin | Myeloma multiplex | Szilárd daganatok | Leukémia, limfocitás, krónikus. B-Cell
-
Assistance Publique - Hôpitaux de ParisMég nincs toborzásLimfóma, B-sejt | Myeloma multiplex | Akut limfoblasztikus leukémia | Hematológiai rosszindulatú daganat | Autó T- CellFranciaország
-
Essen BiotechMég nincs toborzásT-sejtes limfóma | T-sejtes prolimfocita leukémia | T-sejtes akut limfoblasztos leukémia | T-sejtes leukémia | A központi idegrendszer T-sejtes limfómája | T Cell Childhood ALLKína
-
National Cancer Institute (NCI)Aktív, nem toborzóLágyszöveti szarkóma | Osteosarcoma | Ewing szarkóma | Rosszindulatú glioma | Ependimoma | Rhabdoid daganat | Előrehaladott rosszindulatú szilárd daganat | Tűzálló rosszindulatú szilárd daganat | Rhabdomyosarcoma | Ismétlődő rosszindulatú szilárd daganat | Ismétlődő neuroblasztóma | Tűzálló neuroblasztóma | Tűzálló... és egyéb feltételekEgyesült Államok, Puerto Rico